Skip to main content
Advertisement
Advertisement
XENE
XENE logo
Xenon Pharmaceuticals Inc
37.56
USD
Sponsored
-0.19
-0.50%
Nov 19, 15:59 UTC -5
Closed
exchange

After-Market

37.89

+0.33
+0.87%

Xenon Pharmaceuticals Inc (XENE) Earnings

XENE Earnings Reports

Positive Surprise Ratio

XENE beat 26 of 44 last estimates.

59%

Next Report

Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$919.02K
/
-$1.16
Implied change from Q3 26 (Revenue/ EPS)
--
/
+4.50%
Implied change from Q4 25 (Revenue/ EPS)
--
/
-11.45%

Xenon Pharmaceuticals Inc earnings per share and revenue

On Nov 09, 2026, XENE reported earnings of -1.11 USD per share (EPS) for Q3 26, beating the estimate of -1.15 USD, resulting in a 4.03% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.32% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 12 analysts forecast an EPS of -1.16 USD, with revenue projected to reach 919.02 thousand USD, implying an increase of 4.50% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Invivyd, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+26.47%
logo
Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%
logo
Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q1 27
Estimate
-$0.26
Actual
-$0.20
Surprise
+23.61%
logo
Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%
logo
Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%
logo
Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%
logo
Lantern Pharma Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.81
Surprise
-126.89%
logo
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
logo
Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-
Actual
-$0.34
Surprise
-
FAQ
For Q3 2026, Xenon Pharmaceuticals Inc reported EPS of -$1.11, beating estimates by 4.03%, and revenue of $0.00, 0% as expectations.
The stock price moved up 2.32%, changed from $40.45 before the earnings release to $41.39 the day after.
The next earning report is scheduled for Feb 24, 2027.
Based on 12 analysts, Xenon Pharmaceuticals Inc is expected to report EPS of -$1.16 and revenue of $919.02K for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement